secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2025-12-01T23:59:59+00:00
Accession:  0001104659-25-117144
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune CEO Vipin Garg to step down Jan 1, 2026; Chairman Jerome Durso named successor
--------------------------------------------------------------------------------

- Vipin Garg transitions from President/CEO to advisor through June 30, 2026; remains on board until Jan 31, 2026.
- Jerome Durso, current Chairman and former Intercept CEO, becomes President and CEO effective Jan 1, 2026.
- Durso receives annual base salary of $725,000, target bonus 60% of base, and equity grants of 633,700 RSUs and 1,824,400 stock options.
- Garg will receive severance: 12 months base salary, COBRA subsidy, continued equity vesting through separation date.
- Altimmune expects End-of-Phase 2 FDA meeting this quarter and 48-week IMPACT data before year-end for pemvidutide in MASH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000110465925117144/0001104659-25-117144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000110465925117144/tm2532420d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-117144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer